Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections

J. Alexander Viehman, M. Hong Nguyen, Yohei Doi

Research output: Contribution to journalReview article

86 Citations (Scopus)

Abstract

Acinetobacter baumannii is a leading cause of healthcare-associated infections worldwide. Because of various intrinsic and acquired mechanisms of resistance, most β-lactam agents are not effective against many strains, and carbapenems have played an important role in therapy. Recent trends show many infections are caused by carbapenem-resistant or even extensively drug-resistant (XDR) strains, for which effective therapy is not well established. Evidence to date suggests that colistin constitutes the backbone of therapy, but the unique pharmacokinetic properties of colistin have led many to suggest the use of combination antimicrobial therapy. However, the combination of agents and dosing regimens that delivers the best clinical efficacy while minimizing toxicity is yet to be defined. Carbapenems, sulbactam, rifampin and tigecycline have been the most studied in the context of combination therapy. Most data regarding therapy for invasive, resistant A. baumannii infections come from uncontrolled case series and retrospective analyses, though some clinical trials have been completed and others are underway. Early institution of appropriate antimicrobial therapy is shown to consistently improve survival of patients with carbapenem-resistant and XDR A. baumannii infection, but the choice of empiric therapy in these infections remains an open question. This review summarizes the most current knowledge regarding the epidemiology, mechanisms of resistance, and treatment considerations of carbapenem-resistant and XDR A. baumannii.

Original languageEnglish
Pages (from-to)1315-1333
Number of pages19
JournalDrugs
Volume74
Issue number12
DOIs
Publication statusPublished - 01-08-2014
Externally publishedYes

Fingerprint

Acinetobacter Infections
Acinetobacter baumannii
Carbapenems
Pharmaceutical Preparations
Colistin
Therapeutics
Sulbactam
Lactams
Rifampin
Cross Infection
Infection
Epidemiology
Pharmacokinetics
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Viehman, J. Alexander ; Nguyen, M. Hong ; Doi, Yohei. / Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. In: Drugs. 2014 ; Vol. 74, No. 12. pp. 1315-1333.
@article{a31fe07d80314e4bb9cd59f9b8e8f398,
title = "Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections",
abstract = "Acinetobacter baumannii is a leading cause of healthcare-associated infections worldwide. Because of various intrinsic and acquired mechanisms of resistance, most β-lactam agents are not effective against many strains, and carbapenems have played an important role in therapy. Recent trends show many infections are caused by carbapenem-resistant or even extensively drug-resistant (XDR) strains, for which effective therapy is not well established. Evidence to date suggests that colistin constitutes the backbone of therapy, but the unique pharmacokinetic properties of colistin have led many to suggest the use of combination antimicrobial therapy. However, the combination of agents and dosing regimens that delivers the best clinical efficacy while minimizing toxicity is yet to be defined. Carbapenems, sulbactam, rifampin and tigecycline have been the most studied in the context of combination therapy. Most data regarding therapy for invasive, resistant A. baumannii infections come from uncontrolled case series and retrospective analyses, though some clinical trials have been completed and others are underway. Early institution of appropriate antimicrobial therapy is shown to consistently improve survival of patients with carbapenem-resistant and XDR A. baumannii infection, but the choice of empiric therapy in these infections remains an open question. This review summarizes the most current knowledge regarding the epidemiology, mechanisms of resistance, and treatment considerations of carbapenem-resistant and XDR A. baumannii.",
author = "Viehman, {J. Alexander} and Nguyen, {M. Hong} and Yohei Doi",
year = "2014",
month = "8",
day = "1",
doi = "10.1007/s40265-014-0267-8",
language = "English",
volume = "74",
pages = "1315--1333",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "12",

}

Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. / Viehman, J. Alexander; Nguyen, M. Hong; Doi, Yohei.

In: Drugs, Vol. 74, No. 12, 01.08.2014, p. 1315-1333.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections

AU - Viehman, J. Alexander

AU - Nguyen, M. Hong

AU - Doi, Yohei

PY - 2014/8/1

Y1 - 2014/8/1

N2 - Acinetobacter baumannii is a leading cause of healthcare-associated infections worldwide. Because of various intrinsic and acquired mechanisms of resistance, most β-lactam agents are not effective against many strains, and carbapenems have played an important role in therapy. Recent trends show many infections are caused by carbapenem-resistant or even extensively drug-resistant (XDR) strains, for which effective therapy is not well established. Evidence to date suggests that colistin constitutes the backbone of therapy, but the unique pharmacokinetic properties of colistin have led many to suggest the use of combination antimicrobial therapy. However, the combination of agents and dosing regimens that delivers the best clinical efficacy while minimizing toxicity is yet to be defined. Carbapenems, sulbactam, rifampin and tigecycline have been the most studied in the context of combination therapy. Most data regarding therapy for invasive, resistant A. baumannii infections come from uncontrolled case series and retrospective analyses, though some clinical trials have been completed and others are underway. Early institution of appropriate antimicrobial therapy is shown to consistently improve survival of patients with carbapenem-resistant and XDR A. baumannii infection, but the choice of empiric therapy in these infections remains an open question. This review summarizes the most current knowledge regarding the epidemiology, mechanisms of resistance, and treatment considerations of carbapenem-resistant and XDR A. baumannii.

AB - Acinetobacter baumannii is a leading cause of healthcare-associated infections worldwide. Because of various intrinsic and acquired mechanisms of resistance, most β-lactam agents are not effective against many strains, and carbapenems have played an important role in therapy. Recent trends show many infections are caused by carbapenem-resistant or even extensively drug-resistant (XDR) strains, for which effective therapy is not well established. Evidence to date suggests that colistin constitutes the backbone of therapy, but the unique pharmacokinetic properties of colistin have led many to suggest the use of combination antimicrobial therapy. However, the combination of agents and dosing regimens that delivers the best clinical efficacy while minimizing toxicity is yet to be defined. Carbapenems, sulbactam, rifampin and tigecycline have been the most studied in the context of combination therapy. Most data regarding therapy for invasive, resistant A. baumannii infections come from uncontrolled case series and retrospective analyses, though some clinical trials have been completed and others are underway. Early institution of appropriate antimicrobial therapy is shown to consistently improve survival of patients with carbapenem-resistant and XDR A. baumannii infection, but the choice of empiric therapy in these infections remains an open question. This review summarizes the most current knowledge regarding the epidemiology, mechanisms of resistance, and treatment considerations of carbapenem-resistant and XDR A. baumannii.

UR - http://www.scopus.com/inward/record.url?scp=85027927095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027927095&partnerID=8YFLogxK

U2 - 10.1007/s40265-014-0267-8

DO - 10.1007/s40265-014-0267-8

M3 - Review article

C2 - 25091170

AN - SCOPUS:85027927095

VL - 74

SP - 1315

EP - 1333

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 12

ER -